Natera, Inc. (NASDAQ:NTRA) Shares Sold by Jag Capital Management LLC

Jag Capital Management LLC lowered its position in Natera, Inc. (NASDAQ:NTRA) by 41.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,285 shares of the medical research company’s stock after selling 72,305 shares during the quarter. Natera comprises approximately 2.3% of Jag Capital Management LLC’s investment portfolio, making the stock its 14th biggest holding. Jag Capital Management LLC owned 0.08% of Natera worth $16,350,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in NTRA. Blue Trust Inc. increased its stake in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 97 shares during the period. Versant Capital Management Inc increased its stake in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares during the period. Covestor Ltd increased its stake in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the period. Principal Securities Inc. boosted its holdings in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after buying an additional 59 shares in the last quarter. Finally, True Wealth Design LLC bought a new stake in Natera during the third quarter worth approximately $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on NTRA shares. The Goldman Sachs Group raised their target price on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. TD Cowen raised their target price on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Guggenheim raised their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Sanford C. Bernstein raised their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, January 10th. Finally, Robert W. Baird raised their target price on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $172.69.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 78,553 shares of Natera stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the transaction, the chief executive officer now owns 267,629 shares in the company, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John Fesko sold 663 shares of Natera stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares in the company, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 208,299 shares of company stock worth $34,948,265. 7.60% of the stock is owned by corporate insiders.

Natera Stock Down 8.0 %

Natera stock opened at $143.11 on Tuesday. The company has a market capitalization of $18.89 billion, a P/E ratio of -81.31 and a beta of 1.66. The firm’s fifty day simple moving average is $167.44 and its 200-day simple moving average is $147.35. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.